US Telehealth Competitive
Landscape 2026

The US telehealth market in 2026 is not a single competitive arena — it is two adjacent markets with different buyers, different pricing logic, and different growth trajectories. The enterprise segment, dominated by Teladoc Health and Amwell, sells to employers and health systems through multi-year contracts priced per member per month or, increasingly, per visit. The consumer segment, led by Hims & Hers and contested by Amazon Clinic, sells directly to patients — often for specific conditions like weight management, hair loss, erectile dysfunction, and mental health — on a subscription or per-order basis.

The boundary between these segments is the insurance contract. Enterprise players need payer relationships to get reimbursed and to win employer benefit deals. Consumer players have historically grown faster by avoiding that complexity — charging patients directly at prices the market will bear. The risk is that as chronic disease management becomes telehealth's largest growth category, insurance coverage will matter more, and the platforms that built outside payer networks will face an expensive catch-up.

Teladoc's integrated care revenue of $1.6 billion in 2025 dwarfs Amwell's $249.3 million, but Hims & Hers' trajectory from $872 million in 2023 revenue with its May 2025 $850 million raise signals that the consumer model is not a niche — it is a structurally different bet on where healthcare purchasing power is moving.[Teladoc IR][Amwell IR][Landbase]

The five most active named competitors in US telehealth in 2026 are operating fundamentally different business models. Understanding each player's theory of winning — not just their product features — is the essential analytical lens. Teladoc wins through enterprise integration. Amwell wins through health system software licensing. Hims & Hers wins through condition-specific consumer brands. Amazon Clinic wins through purchasing infrastructure. MDLive wins through payer network depth.

What is notable is that none of these five have the same primary customer. Teladoc's primary buyer is the large employer or health plan. Amwell's is the hospital system CIO. Hims & Hers' is the 25–45-year-old with a specific, stigmatised condition. Amazon Clinic's is the Prime subscriber with a minor acute complaint. MDLive's is the regional insurer. This fragmentation explains why no single player has achieved dominant market share — the market has not yet consolidated around a single buyer type.[Fierce Healthcare][Teladoc IR][Amwell IR]

In the enterprise segment, the primary purchase decision is made by benefits directors at large employers or by clinical and IT leadership at hospital systems. The criteria are contract reliability, EHR integration, payer reimbursement coverage, and the ability to report utilisation data back to the buyer. Clinical quality is a threshold requirement, not a differentiator — every platform claims equivalent outcomes. What actually determines the contract award is integration depth: can the telehealth visits flow into the existing EHR, get billed through existing payer relationships, and appear in the employer's benefits portal without friction?

This is why Amwell's $132.4 million subscription revenue base is stickier than its declining headline number suggests — health systems do not replace embedded clinical workflow software lightly.[Amwell IR] Teladoc's shift to visit-based pricing is partly a response to employers demanding proof of utilisation before renewing per-member contracts — a structure that rewards the platform generating the most actual visits, not the most contracted members.[Fierce Healthcare]

In the consumer segment, the winning mechanism is entirely different. Hims & Hers wins through condition-specific brand authority — men and women seeking treatment for hair loss, weight management, or sexual health choose Hims & Hers because the brand signals discretion, clinical legitimacy, and subscription convenience simultaneously. Amazon Clinic wins through zero-friction access: a Prime subscriber with a UTI or a skin rash can initiate a consultation in under three minutes without leaving the Amazon app. Neither of these is a clinical quality story — both are distribution and trust stories.

The platforms that will struggle over the next 18 months are those caught between models: large enough to have enterprise overhead, but not integrated deeply enough to defend enterprise contracts against Teladoc's scale, and not consumer-branded enough to compete with Hims & Hers on direct acquisition. MDLive avoids this trap by being fully absorbed into Cigna's infrastructure — its competitive survival does not depend on being chosen, only on being the default.

Teladoc's consumer-facing price for a direct-to-consumer visit starts at $89 per visit, with variation by specialty.[Teladoc IR] Its enterprise model has historically been priced per member per month (PMPM) under multi-year contracts, but 2026 marks a deliberate transition toward visit-based revenue — a move that shifts risk from the platform to the utilisation rate. If members do not use the service, Teladoc no longer gets paid. That is a meaningful change in competitive incentive.

Confirmed pricing data for Amwell, Amazon Clinic, Hims & Hers, and MDLive is not publicly available in the sources reviewed for this report. Amazon Clinic has historically offered fixed-price messaging consultations for specific conditions (reportedly $35–75 per condition), but this is not confirmed in current filings. Hims & Hers operates on a subscription model where condition-specific monthly plans bundle medication, clinician review, and ongoing management — pricing varies by condition but is designed to undercut traditional cash-pay specialist visits. The absence of published pricing across most platforms is itself a competitive signal: platforms selling through employers and payers have no reason to advertise list prices, while consumer platforms use pricing as a conversion tool.

The strategic implication of Teladoc's visit-based pivot is that per-member-per-month contracts — which rewarded platform scale regardless of engagement — are losing credibility with buyers. Employers increasingly demand proof of member utilisation before renewing. Any platform that cannot demonstrate engagement data will face pricing pressure at renewal. This favours platforms with embedded workflows (Amwell in health systems, MDLive in Cigna) and AI-driven engagement tools (Teladoc's 2025 clinical decision support expansion) over those relying on passive membership.[Fierce Healthcare]

The most meaningful confirmed strategic moves in this market between 2024 and mid-2026 come primarily from Teladoc Health and Hims & Hers — the two players with the most to gain from repositioning. Teladoc's April 2025 expansion of its AI-powered virtual care platform, integrating clinical decision support tools for physicians, signals a deliberate move upstream: instead of being the platform that connects patients to doctors, Teladoc wants to be the platform that makes doctors more effective — creating stickiness at the clinician level rather than just the patient level.[Vocal Media]

Hims & Hers' acquisition of Zava — a European telehealth platform — alongside the acquisition of Trybe Labs for diagnostic capabilities, signals a different ambition: vertical integration of the full care pathway from online consultation through diagnostics to medication delivery, all within a cash-pay subscription model.[Landbase] The $850 million raise in May 2025 gives Hims & Hers the capital to pursue this aggressively. BetterHelp's move to accept insurance within the Teladoc structure is notable precisely because it marks the moment the largest consumer mental health platform acknowledged that cash-pay alone cannot sustain growth in a market where employer-sponsored coverage is the primary payer for behavioral health.

Confirmed strategic moves for Amwell, Amazon Clinic, CVS Health virtual care, and MDLive in this window are not available in the sources reviewed. The absence of confirmed announcements for Amwell is consistent with a company in defensive mode — protecting existing health system contracts rather than expanding. Amazon Clinic's strategy is inferable from its structure (Prime integration, fixed-price acute care) but lacks confirmed 2024–2026 moves in the public record.

The structural forces shaping the US telehealth market in 2026 are unusual because the most powerful external force — government reimbursement policy — is also the most uncertain. CMS telehealth reimbursement policy, extended multiple times since the COVID-19 public health emergency, remains the primary gating factor for enterprise telehealth growth. Every time CMS has been required to reauthorise telehealth payment parity, the market has experienced contract uncertainty. Teladoc's ACA subsidy exposure — driving its membership decline — is the most visible example of how regulatory change can undercut a business model faster than any competitive move.[Teladoc IR]

Supplier power is moderate. The clinical workforce — physicians, nurse practitioners, mental health clinicians — can choose which platform to practice on, and clinician shortages in behavioral health and primary care give them pricing leverage. However, the platforms that have built the deepest AI-assisted workflows (Teladoc's clinical decision support) are beginning to reduce their dependency on any individual clinician by making each clinician more productive. That dynamic, if it scales, shifts power back toward platforms.

Buyer power in the enterprise segment is growing. Employers and health plans now have multiple credible platform options and are increasingly demanding utilisation data and clinical outcome metrics as conditions of contract renewal — moving from 'is telehealth available to our employees' to 'are our employees using it and is it working.' That shift rewards platforms with strong engagement infrastructure and punishes those that rely on passive membership. New entrant threat is real but concentrated: Amazon is the only new entrant with the distribution infrastructure to threaten incumbents at scale, and it has chosen to compete in acute, low-complexity care rather than chronic or specialty care — avoiding the highest-value segments for now.

No verified patient review data from G2, Trustpilot, Apple App Store, or Reddit exists in the sources reviewed for this report for Teladoc, Amwell, Hims & Hers, MDLive, or Amazon Clinic in 2025–2026. The absence of this data is itself a finding: none of these platforms has invested in building a public review presence on third-party platforms the way B2B SaaS companies do, which means sentiment data flows primarily through employer benefits surveys and internal platform reporting rather than public channels.

Teladoc's own 2025 Health System Survey found that 26% of hospital leaders view virtual care quality as superior to in-person care, with improving access — not clinical outcomes — cited as the primary benefit.[Teladoc HHS Survey] This self-reported data is directionally useful but structurally biased toward positive framing. The most credible available insight on unmet needs comes from the structural design failures visible in each platform's model: enterprise platforms create friction at the point of access (complex logins, benefits portal navigation, narrow provider panels), while consumer platforms create friction at the point of care continuity (lack of EHR integration means every visit starts from scratch).

The most likely 18–24-month outcome is that the enterprise segment consolidates further — Teladoc defends its position through visit-based pricing and AI-enhanced workflows, Amwell loses additional revenue and becomes either an acquisition target or a pure health-system software play, and the consumer segment continues to grow faster than enterprise but remains structurally separate. CMS reimbursement policy is the single most important variable: if permanent parity is enacted, every enterprise player benefits and the case for building payer-integrated infrastructure is validated. If parity lapses, consumer-direct models accelerate as patients stop relying on insurer-covered telehealth.

The bear case is that Amazon moves upstream into chronic care, using Prime's distribution and Amazon Pharmacy's medication management infrastructure to offer a vertically integrated alternative to both Teladoc's enterprise model and Hims & Hers' condition subscriptions. No confirmed Amazon move in this direction exists in current filings — but the infrastructure to execute it is already assembled. A founder or investor should watch Amazon's specialist network expansion and any health plan partnership announcements as the leading indicator of this scenario activating.